, Volume 218, Issue 3, pp 493–502 | Cite as

Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study

  • Jon E. GrantEmail author
  • Brian L. Odlaug
  • Samuel R. Chamberlain
  • Suck Won Kim
Original Investigation



Trichotillomania is characterized by repetitive pulling causing noticeable hair loss. Pharmacological treatment data for trichotillomania are limited.


Dronabinol appears to reduce the exocitotoxic damage caused by glutamate release in the striatum and offers promise in reducing compulsive behavior.


Fourteen female subjects (mean age = 33.3 ± 8.9) with DSM-IV trichotillomania were enrolled in a 12-week open-label treatment study of dronabinol (dose ranging from 2.5–15 mg/day). The primary outcome measure was change from baseline to study endpoint on the Massachusetts General Hospital Hair Pulling Scale (MGH-HPS). In order to evaluate effects on cognition, subjects underwent pre- and post-treatment assessments using objective computerized neurocognitive tests. Data were collected from November 2009 to December 2010.


Twelve of the 14 subjects (85.7%) completed the 12-week study. MGH-HPS scores decreased from a mean of 16.5 ± 4.4 at baseline to 8.7 ± 5.5 at study endpoint (p = 0.001). Nine (64.3%) subjects were “responders” (i.e., ≥35% reduction on the MGH-HPS and “much or very much improved” Clinical Global Impression scale). The mean effective dose was 11.6 ± 4.1 mg/day. The medication was well-tolerated, with no significant deleterious effects on cognition.


This study, the first to examine a cannabinoid agonist in the treatment of trichotillomania, found that dronabinol demonstrated statistically significant reductions in trichotillomania symptoms, in the absence of negative cognitive effects. Pharmacological modulation of the cannabinoid system may prove useful in controlling a range of compulsive behaviors. Given the small sample and open-label design, however larger placebo-controlled studies incorporating cognitive measures are warranted.


Cannabinoid Impulsivity Cognition CANTAB CB1 CB2 



This study was funded by internal research funds.

Disclosures/conflicts of interest

Dr. Grant has received research grants from NIMH, NIDA, National Center for Responsible Gaming and its affiliated Institute for Research on Gambling Disorders, and Forest Pharmaceuticals. Dr. Grant receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies. Dr. Grant has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. Mr. Odlaug has received royalties from Oxford University Press. Dr. Chamberlain has consulted for Cambridge Cognition, P1Vital, and Shire Pharmaceuticals. Dr. Kim reports no financial or other relationship relevant to the subject of this article.


  1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, D.C., text revisionGoogle Scholar
  2. Aron AR, Robbins TW, Poldrack RA (2004) Inhibition and the right inferior frontal cortex. Trends Cogn Sci 8:170–177PubMedCrossRefGoogle Scholar
  3. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV (1995) Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89–97PubMedCrossRefGoogle Scholar
  4. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7–14PubMedCrossRefGoogle Scholar
  5. Benito C, Romero JP, Tolón RM, Clemente D, Docagne F, Hillard CJ, Guaza C, Romero J (2007) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27:2396–2402PubMedCrossRefGoogle Scholar
  6. Bienvenu OJ, Wang Y, Shugart YY et al (2009) Sapap3 and pathological grooming in humans: results from the OCD collaborative genetics study. Am J Med Genet B Neuropsychiatr Genet 150B:710–720PubMedCrossRefGoogle Scholar
  7. Calhoun SR, Galloway GP, Smith DE (1998) Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 30(2):187–196PubMedCrossRefGoogle Scholar
  8. Cambridge Cognition Limited (2006) CANTABeclipse, version 3. Cambridge Cognition Limited, CambridgeGoogle Scholar
  9. Chamberlain SR, Sahakian BJ (2007) The neuropsychiatry of impulsivity. Curr Opin Psychiatry 20:255–261PubMedGoogle Scholar
  10. Chamberlain SR, Hampshire A, Menzies LA, Garyfallidis E, Grant JE, Odlaug BL, Craig K, Fineberg N, Sahakian BJ (2010a) Reduced brain white matter integrity in trichotillomania: a diffusion tensor imaging study. Arch Gen Psychiatry 67:965–971PubMedCrossRefGoogle Scholar
  11. Chamberlain SR, Robbins TW, Winder-Rhodes S, Müller U, Sahakian BJ, Blackwell AD, Barnett JH (2010b). Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery. Biol Psychiatry. doi: 10.1016/j.biopsych.2010.08.019
  12. Christenson GA, Mansueto CS (1999) Trichotillomania: descriptive characteristics and phenomenology. In: Stein DJ, Christianson GA, Hollander E (eds) Trichotillomania. American Psychiatric Press, Washington, D.C., pp 1–41Google Scholar
  13. Christenson GA, Mackenzie TB, Mitchell JE (1991a) Characteristics of 60 adult chronic hair pullers. Am J Psychiatry 148:365–370PubMedGoogle Scholar
  14. Christenson GA, Mackenzie TB, Mitchell JE, Callies AL (1991b) A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 148:1566–1571PubMedGoogle Scholar
  15. Clark L (2010) Decision-making during gambling: an integration of cognitive and psychobiological approaches. Philos Trans R Soc Lond B Biol Sci 365:319–330PubMedCrossRefGoogle Scholar
  16. Clark L, Bechara A, Damasio H, Aitken MR, Sahakian BJ, Robbins TW (2008) Differential effects of insular and ventromedial prefrontal cortex lesions on risky decision-making. Brain 131:1311–1322PubMedCrossRefGoogle Scholar
  17. De Chiara V, Angelucci F, Rossi S et al (2010) Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum. J Neurosci 30:8127–8137PubMedCrossRefGoogle Scholar
  18. Diefenbach GJ, Tolin DF, Hannan S, Maltby N, Crocetto J (2006) Group treatment for trichotillomania: behavior therapy versus supportive therapy. Behav Ther 37:353–363PubMedCrossRefGoogle Scholar
  19. Dougherty DD, Loh R, Jenike MA, Keuthen NJ (2006) Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry 67:1086–1092PubMedCrossRefGoogle Scholar
  20. Dumont G, van Hasselt J, de Kam M, van Gerven J, Dj T, Buitelaar J, Verkes R (2011) Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers. J Psychopharmacol 25:478–489PubMedCrossRefGoogle Scholar
  21. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New YorkGoogle Scholar
  22. Flessner CA, Woods DW, Franklin ME, Cashin SE, Keuthen NJ, Trichotillomania Learning Center-Scientific Advisory Board (TLC-SAB) (2008) The Milwaukee Inventory for Subtypes of Trichotillomania-Adult Version (MIST-A): development, exploratory factor analysis, and psychometric properties. J Psychopathol Behav Assess 30:20–30CrossRefGoogle Scholar
  23. Frisch MB, Cornell J, Villaneuva M (1993) Clinical validation of the quality of life inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess 4:92–101CrossRefGoogle Scholar
  24. Gadde KM, Ryan Wagner H 2nd, Connor KM, Foust MS (2007) Escitalopram treatment of trichotillomania. Int Clin Psychopharmacol 22:39–42PubMedCrossRefGoogle Scholar
  25. Gerdeman GL, Ronesi J, Lovinger DM (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5:446–451PubMedGoogle Scholar
  26. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327–5333PubMedGoogle Scholar
  27. Grant JE, Odlaug BL, Kim SW (2009) N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 66:756–763PubMedCrossRefGoogle Scholar
  28. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM). National Institute of Mental Health, Rockville, pp 76–338Google Scholar
  29. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedCrossRefGoogle Scholar
  30. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62PubMedCrossRefGoogle Scholar
  31. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932–1936PubMedCrossRefGoogle Scholar
  32. Hunault CC, Mensinga TT, Böcker KB, Schipper CM, Kruidenier M, Leenders ME, de Vries I, Meulenbelt J (2009) Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) 204:85–94CrossRefGoogle Scholar
  33. Jager G, Ramsey NF (2008) Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev 1:114–123PubMedCrossRefGoogle Scholar
  34. Keuthen NJ, O’Sullivan RL, Ricciardi JN, Shera D, Savage CR, Borgmann AS, Jenike MA, Baer L (1995) The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. Development and factor analyses. Psychother Psychosom 64:141–145PubMedCrossRefGoogle Scholar
  35. Keuthen NJ, Flessner CA, Woods DW, Franklin ME, Stein DJ, Cashin SE, Trichotillomania Learning Center Scientific Advisory Board (2007) Factor analysis of the Massachusetts General Hospital Hairpulling Scale. J Psychosom Res 62:707–709PubMedCrossRefGoogle Scholar
  36. Keuthen NJ, Rothbaum BO, Falkenstein MJ, Meunier S, Timpano KR, Jenike MA, Welch SS (2011) DBT-enhanced habit reversal treatment for trichotillomania: 3- and 6-month follow-up results. Depress Anxiety 28:310–313PubMedCrossRefGoogle Scholar
  37. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B (2004) Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19:1691–1698PubMedCrossRefGoogle Scholar
  38. Koran LM, Ringold A, Hewlett W (1992) Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull 28:145–149PubMedGoogle Scholar
  39. Lezak MD, Howieson DB, Loring DW et al (2004) Neuropsychological Assessment. Oxford University Press, New YorkGoogle Scholar
  40. Logan GD, Cowan WB, Davis KA (1984) On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform 10:276–291PubMedCrossRefGoogle Scholar
  41. Mailleux P, Vanderhaeghen JJ (1992) Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett 148:173–176PubMedCrossRefGoogle Scholar
  42. Manes F, Sahakian B, Clark L, Rogers R, Antoun N, Aitken M, Robbins T (2002) Decision-making processes following damage to the prefrontal cortex. Brain 125:624–639PubMedCrossRefGoogle Scholar
  43. Marsicano G, Goodenough S, Monory K et al (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84–88PubMedCrossRefGoogle Scholar
  44. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM (2009) The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39:1607–1616PubMedCrossRefGoogle Scholar
  45. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1998) Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98:502–506PubMedCrossRefGoogle Scholar
  46. Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57–61PubMedCrossRefGoogle Scholar
  47. Ninan PT, Knight B, Kirk L, Rothbaum BO, Kelsey J, Nemeroff CB (1998) A controlled trial of venlafaxine in trichotillomania: interim phase I results. Psychopharmacol Bull 34:221–224PubMedGoogle Scholar
  48. Odlaug BL, Kim SW, Grant JE (2010) Quality of life and clinical severity in pathological skin picking and trichotillomania. J Anxiety Disord 24:823–829PubMedCrossRefGoogle Scholar
  49. Owen AM, Morris RG, Sahakian BJ, Polkey CE, Robbins TW (1996) Double dissociations of memory and executive functions in working memory tasks following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Brain 119:1597–1615PubMedCrossRefGoogle Scholar
  50. Rabin RA, Zakzanis KK, George TP (2011) The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res 128(1–3):111–116PubMedCrossRefGoogle Scholar
  51. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G (2006) Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 85:114–122PubMedCrossRefGoogle Scholar
  52. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23:266–277PubMedCrossRefGoogle Scholar
  53. Ranganathan M, D’Souza DC (2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188:425–444CrossRefGoogle Scholar
  54. Realini N, Rubino T, Parolaro D (2009) Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res 60:132–138PubMedCrossRefGoogle Scholar
  55. Rossi S, De Chiara V, Musella A, Kusayanagi H, Mataluni G, Bernardi G, Usiello A, Centonze D (2008) Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J Neurosci 28:7284–7292PubMedCrossRefGoogle Scholar
  56. Rothbaum BO, Ninan PT (1994) The assessment of trichotillomania. Behav Res Ther 32:651–662PubMedCrossRefGoogle Scholar
  57. Sheehan DV (1983) The anxiety disease. Scribner’s, New YorkGoogle Scholar
  58. Stein DJ, Bouwer C, Maud CM (1997) Use of the selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania. Eur Arch Psychiatry Clin Neurosci 247:234–236PubMedCrossRefGoogle Scholar
  59. Streichenwein SM, Thornby JI (1995) A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 152:1192–1196PubMedGoogle Scholar
  60. Swedo SE, Leonard HL, Rapoport JL, Lenane MC, Goldberger EL, Cheslow DL (1989) A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 321:497–501PubMedCrossRefGoogle Scholar
  61. Swedo SE, Lenane MC, Leonard HL (1993) Long-term treatment of trichotillomania (hair pulling). N Engl J Med 329:141–142PubMedCrossRefGoogle Scholar
  62. Tolin DF, Franklin ME, Diefenbach GJ, Anderson E, Meunier SA (2007) Pediatric trichotillomania: descriptive psychopathology and an open trial of cognitive behavioral therapy. Cogn Behav Ther 36:129–144PubMedCrossRefGoogle Scholar
  63. Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J (2010) A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 71:1336–1343PubMedCrossRefGoogle Scholar
  64. van der Stelt M, Di Marzo V (2005) Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 7:37–50PubMedCrossRefGoogle Scholar
  65. Winchel RM, Jones JS, Stanley B, Molcho A, Stanley M (1992) Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry 53:304–308PubMedGoogle Scholar
  66. Woods DW, Wetterneck CT, Flessner CA (2006a) A controlled evaluation of acceptance and commitment therapy plus habit reversal for trichotillomania. Behav Res Ther 44:639–656PubMedCrossRefGoogle Scholar
  67. Woods DW, Flessner CA, Franklin ME, Keuthen NJ, Goodwin RD, Stein DJ, Walther MR, Trichotillomania Learning Center-Scientific Advisory Board (2006b) The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization. J Clin Psychiatry 67:1877–1888PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Jon E. Grant
    • 1
    Email author
  • Brian L. Odlaug
    • 1
  • Samuel R. Chamberlain
    • 2
  • Suck Won Kim
    • 1
  1. 1.Department of PsychiatryUniversity of Minnesota School of MedicineMinneapolisUSA
  2. 2.Department of Psychiatry, Addenbrooke’s HospitalUniversity of CambridgeCambridgeUK

Personalised recommendations